George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yep, rocketed up....
Hi All Fantastic RNS just announced today at 13:05 link below
https://www.londonstockexchange.com/news-article/ARIX/clinical-portfolio-update/15014832
The Share Price will rocket up in my opinion when this news is digested GLA
StarKnight
With the share price depressed, and shares being bought back, the discount to nav (both including and excluding cash) must to getting to ridiculous levels now.
The acquisition of Amplyx follows an initial equity investment by Pfizer in December 2019 as part of Amplyx's Series C financing. The terms of the transaction will result in a small increase in Arix's holding value of Amplyx.[1]
The announcement can be accessed on Pfizer's website at: https://www.pfizer.com/news and full text of announcement from Pfizer is contained below
https://www.investorschronicle.co.uk/ideas/2021/04/08/five-investment-company-bargains/
(Try going there via google if you hit a registration barrier.)
"... I suggested buying Arix shares, at 168p, in my market-beating 2021 Bargain Shares Portfolio, and the news from Artios adds further weight to the investment case. Buy."
The sp does not move much with this share, very stable, even on good news. Hopefully a nice steady rise over the medium term.
LSE seems to be missing our RNS's at the moment.
https://www.investegate.co.uk/arix-bioscience-plc--arix-/eqs/artios-announces-collaboration-with-novartis-to-create-next-generation-ddr-cancer-therapies/20210407070002EJNUD/
(Also 06/04/21 RNS: buyback of 87k shares bringing total so far to 800k.)
Hi skid35, you're right of course, perhaps I should have said "appease" rather than "address".
At least giving Acacia more say should reduce the likelihood of them selling into the buyback. Assuming they're not then this will be confirmed when Acacia's holding is nudged over 20%, prompting a TR1. But that won't happen till about half way through the buyback, which is a few months off at the present rate.
Sgd, this isn't a board member appointment, these have been out on hold.
Acacia seem to have a lot of say now in the running of the company. I haven't got a clue what the strategy will be going forward.
The share price is massively underpinned by the discount to nav, the tonne of cash and the buybacks.
Is this to address Acacia's complaint that Arix "lacks gender diversity on the Board"?
Looking at seeing benefits from the share buy back investment funds soon
With the level of cash they had from the sale it would take a while to deploy, and deploy on decent opportunities.
Just wonder whose decision it was ? But as you say good for remaining sbareholders.
Great decision to acquire shares at well below their NAV per share, so increasing the NAV per share for those of us who remain shareholders.
If anyone has a Times subscription (I don't), there's something about the "public spat" here:
https://www.thetimes.co.uk/article/trust-in-big-tech-gives-shareholders-a-boost-ds99hgkr7
https://www.investorschronicle.co.uk/ideas/2021/03/10/clean-up-with-two-deep-value-plays/
"I expect the two parties to come to some arrangement in due course, and continue to see scope for a significant narrowing of Arix’s 23 per cent share price discount to NAV. Moreover, if the board use their authority to buy back up to 10 per cent of the shares outstanding, then the share price discount is likely to narrow rapidly. Buy."
Yes, I would have thought there would have been standardised monthly reviews etc. By refusing a meeting I think the relationship was broken beforehand.
As you say very valid concerns. Not that bothered on diversity, I just want the best people.
If the SID did defer the meeting with a major shareholder several times I can understand them escalating it. There are valid concerns raised in the letter which need answers. However given the discount on net asset value I still rate this a buy.
Try,
I must say really confused this morning having slept in it, and surprised with the share price reaction this morning.
I can see a shareholder with 20% needs to have a good working relationship with the BOD, by going public so quickly and aggressively there seems very little respect between the two parties.
As you say acacia doesn't have a great history and anyone still seeing Woodford as a future partner needs their head examined.
The current share price assumes ARIX, whoever makes the investment decisions, will not invest the cash they have wisely.
Seeing back to watch everyone throw little hissy fits in the meantime.
Good point about SNG.
However, if they can improve the board I can't really see an issue. We'd all be in favour of more experience and knowledge being available for decision making, surely.
Nobody wants to be directed to though.
No surprise that the SP has taken a hit today. People may be worrying that if Acacia don't get their way they'll sell out.
My guess is that they'll reach a compromise, maybe with Acacia getting one seat on the board. Pure speculation of course.
Love the message from Acacia about them wanting two of their lot to be appointed to the Board to bring expertise to investment decision making.
Their self confidence defies credibility.
Acacia obtained their shareholding from buying Woodford's medical portfolio which also included SNG. Acacia chose to hold Arix but sell SNG at 35p ahead of the Phase 2 trial results in July that rocketed the SNG price to 240p. Without intending disrespect to Arix, how much poorer could Acacia have shown their judgement to be? They received a gift & got rid of it.
Yes, short. I guess that there is not much more they could say so quickly.
Though if the events of the past few days has shown anything, they have highlighted the importance of good communications
The response is a brief one, but no doubt there's more to come...
https://www.investegate.co.uk/arix-bioscience-plc--arix-/eqs/response-to-activist-shareholder-acacia/20210310070059ESDLM/